Clarity Capital Partners LLC Grows Position in Tempus AI, Inc. $TEM

Key Points

• Clarity Capital Partners LLC increased its position in Tempus AI, Inc. by 65.1% in the second quarter, owning 80,147 shares valued at approximately $5.09 million.
• Vanguard Group Inc. significantly boosted its stake in Tempus AI by 6,247.5%, now holding nearly six million shares worth about $289 million.
• Tempus AI beat analysts' expectations with earnings per share of ($0.22) for the last quarter and reported a revenue surge of 89.5% year-over-year, totaling $314.64 million.

Clarity Capital Partners LLC increased its position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 65.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,147 shares of the company's stock after purchasing an additional 31,611 shares during the period. Tempus AI makes up 1.8% of Clarity Capital Partners LLC's portfolio, making the stock its 13th largest holding. Clarity Capital Partners LLC's holdings in Tempus AI were worth $5,093,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in TEM. Vanguard Group Inc. boosted its stake in shares of Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock worth $289,204,000 after purchasing an additional 5,900,668 shares during the period. ARK Investment Management LLC boosted its position in Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after buying an additional 1,981,755 shares during the period. Nikko Asset Management Americas Inc. boosted its position in Tempus AI by 31.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after buying an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 31.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after buying an additional 1,016,384 shares during the period. Finally, CloudAlpha Capital Management Limited Hong Kong purchased a new stake in Tempus AI in the 1st quarter valued at about $34,119,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Trading Up 2.6%

Shares of NASDAQ:TEM opened at $91.66 on Friday. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $97.79. The business's fifty day simple moving average is $74.98 and its 200-day simple moving average is $63.18. The company has a market capitalization of $15.92 billion, a PE ratio of -77.03 and a beta of 4.87. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business had revenue of $314.64 million for the quarter, compared to the consensus estimate of $296.84 million. During the same period last year, the business posted ($6.86) EPS. The business's revenue was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on TEM. Guggenheim boosted their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, September 26th. Morgan Stanley boosted their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Tuesday, August 12th. HC Wainwright boosted their price objective on shares of Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Needham & Company LLC reissued a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research report on Friday, August 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a research report on Saturday, September 27th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $71.83.

Insider Activity

In related news, CFO James William Rogers sold 7,528 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the transaction, the chief financial officer owned 138,473 shares in the company, valued at $10,337,009.45. The trade was a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Theodore Leonsis sold 44,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total transaction of $3,075,600.00. Following the transaction, the director owned 86,756 shares of the company's stock, valued at approximately $6,064,244.40. This trade represents a 33.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock worth $67,909,393 over the last 90 days. 26.27% of the stock is currently owned by insiders.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.